|
The Safest Bet in Town! (OTCBB: QTXB), (OTCBB: CBIS), (OTCBB: MBYL)
(M2 PressWIRE Via Acquire Media NewsEdge) ****************************************************************************************
PENNY STOCK BETS: www.pennystockbets.com Your Safest Bet in Town!
Don't gamble with your financial future, Subscribe to our FREE newsletter and stay current with the latest stock picks.
*** SIGN UP AT www.pennystockbets.com
***
Earn money without losing anything,Contact us at info@pennystockbets.com
*****************************************************************************************
QuantRx Biomedical Consolidates Operations to Oregon
DOYLESTOWN, Pa., Sep 01, 2010
QuantRx(R) Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide point-of-care healthcare industry, today announced that it will be consolidating its operations in order to better serve its growing market demands. The operational consolidation will expand the Company's presence in Portland, Oregon, and reflects a transition from the developmental stage to an enterprise focused on the marketing and manufacturing of innovative products for advanced diagnosis of serious disease and health conditions.
The Portland consolidation will eliminate various general and administrative overhead costs and requires the relocation of several key operational positions, including all of the Company's accounting and financial personnel. The Company's CFO, Sasha Afanassiev, has elected not to relocate, and will be replaced by the Company as soon as the consolidation effort is complete.
"We need to focus our efforts on bringing our products to the market and found that the separation of our operational units did not facilitate that goal," said Walter Witoshkin, QuantRx Chairman and CEO. "We appreciate the many years of service from Sasha Afanassiev as our CFO, who has consistently done an outstanding job for us and will remain available for consultation to assist during the transition. Our Portland, Oregon operation houses an exceptional team of research and operations personnel, which has developed our new human and veterinary diagnostics platform. As we now move to manufacturing and distribution of our products, the Company requires on-site administrative and accounting support. The consolidation will result in a more efficient and unified organization better suited to implement our growth strategies."."
Dr. William Fleming, QuantRx Chief Scientific Officer and President of its Diagnostics Division, added, "While we have enjoyed working with the Doylestown team and will miss Sasha Afanassiev's contributions, the consolidation will help assure a timely entry to our markets, and develop a superior customer support system."
About QuantRx Biomedical (www.quantrx.com)
QuantRx Biomedical Corporation (OTCBB: QTXB) is focused on the development and commercialization of innovative products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms leveraging a vast portfolio of intellectual property, QuantRx's mission is to introduce products for use by medical professionals, institutions, and consumers that deliver more accurate, reliable, and faster diagnoses which result in improved patient care and a reduction in overall healthcare costs.
The QuantRx strategy targets significant market opportunities estimated to be in excess of $5 billion worldwide. The Company's technology portfolio, with more than three dozen patents, patents pending and licensed patents, includes: (1) RapidSense(R) point-of-care testing products based on QuantRx core intellectual property related to lateral flow techniques for the consumer and healthcare professional markets (QN Diagnostics); (2) PAD technology for over-the-counter applications, and the diagnosis and treatment of women's health concerns and other medical needs, and (3) significant investments in: (a) genome-based diagnostic chips for the laboratory and healthcare professional markets; and (b) molecular imaging agents for positron emission tomography (PET) and fluorescence imaging, with initial application in cardiovascular disease, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment.
This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, management's current plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including; general economic conditions, the Company's need for additional funds, the early state of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the Company's ability to avoid infringement of the patent rights of others, and the Company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. QuantRx does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.
-----------------------------------------------------------------------------------------
Cannabis Science Reports on Multi-Billion Dollar Chronic Pain Market as Canadian Medical Journal Publishes Study That "Smoked Marijuana" is Effective Against Neuropathic Pain That Does Not Respond to Conventional Treatment
COLORADO SPRINGS, Colo., Sep 1, 2010
Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment. In this multi-billion dollar market, this is very encouraging news for Cannabis Science shareholders as even small doses of cannabis provided relief from chronic, neuropathic pain, which may be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Neuropathic pain is also common in cancer patients as a direct result of the cancer, or as a side effect of chemotherapy, radiation or surgery.
Cannabis Science President and CEO Dr. Robert Melamede, PhD., commented, "Obviously, this study gives further support to our plans to work within the multi-billion dollar market of chronic neuropathic pain. As Dr. Ware said at the beginning of the CMAJ article, cannabis sativa has been used to treat pain since the third millennium BC, so it is all the more outrageous that it has taken so long for such a study to be done, and it could only be used by patients who did not respond to anything else. Why do they have to suffer so much to prove what almost all medical marijuana users already know?"
McGill's study is the first double-blind, placebo-controlled trial conducted with outpatients who were allowed to smoke marijuana in their own homes. Participants were divided into four groups and randomly assigned marijuana containing four levels of tetrahydrocannabinol (THC), the active ingredient: at 9.4 per cent, 6.0 per cent, 2.5 per cent, and zero THC. The study was led by anesthesiologist Mark Ware, director of clinical research at Montreal's Alan Edwards Pain Management Unit at the McGill University Health Centre. It was published in the Canadian Medical Association Journal. Please see: http://www.cmaj.ca/cgi/rapidpdf/cmaj.091414v1?ijkey=44cf2a4e01bb03581946f0ab6b7217d7a6e78f0b
Richard Cowan, Cannabis Science CFO, added, "This study demonstrates the importance of our licensing agreement with the RockBrook dispensary of Denver which we announced on August 18th, which gives us the immediate ability to test our formulations with humans to help determine exactly what doses and strains work best for patients as we prepare to enter clinical trials."?See?http://cannabisscience.com/news-a-media/press-releases/200-cbis-signs-first-licensing-agreement-with-rockbrook.html
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
-----------------------------------------------------------------------------------------
Mobile Data Corp Announces Video Corporate Update
SAN JOSE, Sept 01, 2010
Mobile Data Corp. (OTCBB: MBYL) is pleased to inform our shareholders that the Company continues to develop the MDC-Tracker software application to provide additional benefits to the end user. As part of our membership in the Research in Motion (RIM) BlackBerry Alliance Program we are committed to enhancing our corporate presence and product line-up. To this end we have posted a video message from Steve Cozine, President & CEO on the website to give the public another tool to gather information about what we're doing and where we are going. This initial video will be updated and replaced with new video announcements as developments become relevant and news worthy.
Video communication has become the most effective method of starting and continuing a dialogue with interested parties, and MDC has adopted the medium to provide a face to our corporate information dissemination commitment.
Please visit www.mobiledatecorp.com to view the new video and feel free to contact Steve Cozine at steve@mobiledatacorp.com with comments or questions.
Concurrently, a new website is currently under construction and it is anticipated to debut by months end.
The MDC-Tracker application can be downloaded directly from the Company's website, www.mobiledatacorp.com. The Company anticipates that the product will also be available from the Research In Motion BlackBerry App Store, in the near term. The MDC-Tracker application provides users with a historical archive of global positioning coordinates over any given period of time. This means that a user will be able to know the history of where a BlackBerry Smartphone has been at various points during the day, week, month or any other prescribed time frame.
Further information about Mobile Data Corp. and the MDC-Tracker may be obtained from the company's website at www.mobiledatacorp.com. Mobile Data Corp is a solutions provider for telecommunications and computer convergence.
Safe Harbor Statement ---------------------
Forward-looking statements in this news release are made pursuant to the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used herein, words such as "intend" and similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on assumptions made by and information available to Mobile Data Corp. Investors are cautioned that such forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, without limitation, continued acceptance of Mobile's products, technological changes and the successful development of new products, dependence on third-party networks to provide services, dependence on intellectual property rights, increased levels of competition, possible product defects and product liability, changes in Canadian and foreign laws and regulations, significant fluctuations of quarterly operating results, risks related to international sales and potential foreign currency exchange fluctuations, the initiation or outcome of litigation, acts or potential acts of terrorism, international conflicts, and other risks and factors detailed from time to time in Mobile's periodic reports filed with the United States Securities and Exchange Commission, and other regulatory authorities. Should one or more of these risks or uncertainties materialize, or should any of Mobile's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Mobile's forward-looking statements. Except as required by law, Mobile disclaims any obligation to update or public announce any revisions to any of the forward-looking statements contained in this press release. This communication to shareholders and the public contains certain forward-looking statements.
*****************************************************************************************
About PennyStockBets.comPennyStockBets.com is written and published by PennyStockBets.com employees. Readers are advised that this analysis report is issued solely for informational purposes. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. PennyStockBets.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. For additional information, please visit www.PennyStockBets.com or e-mail info@PennyStockBets.com.
((Comments on this story may be sent to info@m2.com))
(c) 2010 M2 COMMUNICATIONS
[ Back To Homepage ]
|
